Analyzing Revvity (RVTY) & Its Peers

Revvity (NYSE:RVTY) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it compare to its peers? We will compare Revvity to similar businesses based on the strength of its profitability, risk, valuation, earnings, institutional ownership, dividends and analyst recommendations.

Volatility and Risk

Revvity has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Revvity’s peers have a beta of 0.93, meaning that their average stock price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Revvity and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0	13	6	0	2.32
Revvity Competitors	953	3176	5509	178	2.50

Revvity presently has a consensus target price of $133.86, suggesting a potential downside of 13.82%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 2.04%. Given Revvity’s peers stronger consensus rating and higher probable upside, analysts clearly believe Revvity has less favorable growth aspects than its peers.

Insider & Institutional Ownership

86.7% of Revvity shares are held by institutional investors. Comparatively, 54.0% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 0.9% of Revvity shares are held by company insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Revvity and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revvity	8.61%	8.64%	5.24%
Revvity Competitors	-539.85%	77.36%	-13.47%

Earnings and Valuation

This table compares Revvity and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Revvity	$2.86 billion	$241.20 million	68.73
Revvity Competitors	$2.25 billion	$55.11 billion	-7.83

Revvity has higher revenue, but lower earnings than its peers. Revvity is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Dividends

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Revvity pays out 12.4% of its earnings in the form of a dividend. As a group, “Life Sciences Tools & Services” companies pay a dividend yield of 8.3% and pay out 44.6% of their earnings in the form of a dividend.

Summary

Revvity peers beat Revvity on 8 of the 15 factors compared.

About Revvity

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.